Bexotegrast(Bexotegrast) - 药物靶点：αvβ1 x αvβ6_在研适应症：特发性肺纤维化，原发性硬化性胆管炎，肝纤维化_专利_临床

概要

基本信息

药物类型

小分子化药

别名

PLN 74809、PLN-74809

靶点

αvβ1 x αvβ6

作用机制

αvβ1抑制剂(整合素α-V/β-1复合体抑制剂)、αvβ6拮抗剂(整合素α-V/β-6复合体拮抗剂)

治疗领域

消化系统疾病呼吸系统疾病其他疾病

在研适应症

特发性肺纤维化原发性硬化性胆管炎肝纤维化

非在研适应症

新型冠状病毒感染急性呼吸窘迫综合征

原研机构

Pliant Therapeutics, Inc.

在研机构

Pliant Therapeutics, Inc.

非在研机构-

最高研发阶段临床2/3期

首次获批日期-

最高研发阶段(中国)临床2/3期

特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟)

登录后查看时间轴

结构/序列

分子式C27H36N6O3

InChIKeyCWOFQJBATWQSHL-DEOSSOPVSA-N

CAS号2376257-44-0

关联

10

项与 Bexotegrast 相关的临床试验

CTIS2023-506185-31-00

/ Recruiting临床2/3期

A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF) - PLN-74809-IPF-206

开始日期2024-08-08

申办/合作机构

Pliant Therapeutics, Inc.

NCT06097260

/ Recruiting临床2期

A Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy and Safety of Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis (BEACON-IPF)

A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).

开始日期2023-11-16

申办/合作机构

Pliant Therapeutics, Inc.

NCT05621252

/ Completed临床2期

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Evaluation of PLN-74809 on Type 1 Collagen Deposition Using 68Ga-CBP8 PET/MRI Imaging in Participants With Idiopathic Pulmonary Fibrosis (IPF)

This is a Phase 2a, single -center, randomized, double-blind, placebo-controlled study to evaluate type 1 collagen deposition in the lungs following once-daily treatment with PLN-74809 for 12-weeks. This study is occurring at Massachusetts General Hospital.

开始日期2022-07-13

申办/合作机构

Pliant Therapeutics, Inc.

100 项与 Bexotegrast 相关的临床结果

登录后查看更多信息

100 项与 Bexotegrast 相关的转化医学

登录后查看更多信息

100 项与 Bexotegrast 相关的专利（医药）

登录后查看更多信息

8

项与 Bexotegrast 相关的文献（医药）

2024-11-01·EUROPEAN JOURNAL OF PHARMACOLOGY

A dual αvβ1/αvβ6 integrin inhibitor Bexotegrast (PLN-74809) ameliorates organ injury and fibrogenesis in fibrotic kidney disease

Article

作者: Hu, TingTing ; Mu, Yingsong ; Tan, Zhouke ; Liu, Jing ; Wu, Qimei ; Ma, Liang ; Yan, Xiaoyong ; Li, Yiman ; Wang, Bo

Chronic kidney disease (CKD) is a global public health problem, involving about 10% of the global population. Unfortunately, there are currently no effective drugs. Kidney fibrosis is the main pathology of CKD, where integrins play crucial roles in renal fibrogenesis. Recently, Bexotegrast (PLN-74809) as a dual integrin αvβ1/αvβ6 inhibitor could reduce the degree of lung fibrosis in patients with idiopathic pulmonary fibrosis. However, the role of PLN-74809 remains unclear in fibrotic kidney disease. Here, we have revealed that PLN-74809 administration dose-dependently delayed the progression of renal fibrosis in both adenine diet- and unilateral ureteral obstruction (UUO)-induced mice. Mechanistically, PLN-74809 targeted integrin αvβ1/αvβ6 to inhibit FAK/Src/Akt/β-catenin cascade in fibrotic kidneys. In summary, our results for the first time highlighted the αvβ1/αvβ6 inhibitor PLN-74809 exerted potential therapeutic against kidney fibrosis.

2024-09-01·CURRENT OPINION IN PULMONARY MEDICINE

Evidence from recent clinical trials in fibrotic interstitial lung diseases

Review

作者: Valenzuela, Claudia ; Cottin, Vincent

Purpose of review:

Idiopathic pulmonary fibrosis (IPF) is the prototype of fibrosing interstitial lung diseases. It is mirrored by progressive pulmonary fibrosis (PPF), an umbrella term which characterizes disease behavior of various fibrotic interstitial lung diseases with irreversible progression, accounting for loss of lung function, exercise intolerance and respiratory failure leading to early mortality. Pirfenidone and nintedanib halve the decline in lung function but do not halt disease progression.

Recent findings:

Since the publication in 2014 of pivotal pirfenidone and nintedanib studies, a number of clinical trials were conducted, many of them did not reach their primary endpoints. In IPF, promising phase 2 trials were followed by large phase 3 trials that did not confirm a favorable efficacy to tolerability favorable profile, including those with ziritaxestat, an autotaxin-1 inhibitor, zinpentraxin-alpha (human recombinant pentraxin-2), and the monoclonal antibody pamrevlumab targeting connective tissue growth factor. Nevertheless, newer compounds that hold promise are currently being evaluated in phase 3 or phase 2b randomized controlled trials, including: nerandomilast, a preferential phosphodiesterase 4B inhibitor; admilparant, a lysophosphatidic acid receptor antagonist; inhaled treprostinil, a prostacyclin agonist; and bexotegrast, a dual-selective inhibitor of αvβ6 and αvβ1 integrins. Nerandomilast, admilparant, inhaled treprostinil, and inhaled AP01 (pirfenidone), are currently studied in patients with PPF.

Summary:

Despite recent frustrating negative results, there is a growing portfolio of candidate drugs developed in both IPF and PPF.

2024-08-15·AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial

Article

作者: Betensley, Alan ; Ettinger, Neil ; Valenzuela, Claudia ; Barnes, Chris N. ; Mostard, Remy ; Clark, Annie ; Fernandez, Evans ; Goldin, Jonathan ; Wuyts, Wim A. ; Epstein, Matthew D. ; Veltkamp, Marcel ; Lefebvre, Éric A. ; Jurek, Marzena ; Wuyts, Wim ; Richeldi, Luca ; Lefebvre, Éric A ; Turner, Scott ; Ramaswamy, Murali ; Jenkins, R. Gisli ; Zaman, Tanzira ; Achneck, Hardean E. ; Boente, Ryan ; Layish, Daniel ; Jenkins, R Gisli ; Janssen, Robert ; Harari, Sergio ; Wuyts, Wim A ; Gibson, Kevin ; Cottin, Vincent ; Flaherty, Kevin R. ; Antin-Ozerkis, Danielle ; Cosgrove, Gregory P ; Golden, Jeffrey ; Brockway, Benedict (Ben) ; Achneck, Hardean E ; Flaherty, Kevin R ; Noordegraaf, Anton Vonk ; Dhar, Anil ; Case, Amy ; Corte, Tamera ; Veeraraghavan, Srihari ; Ryerson, Christopher J ; Kim, Grace Hyun J ; Montessi, Sydney ; Sager, Jeffrey ; Baratz, David ; Lancaster, Lisa ; Beckert, Lutz ; Barnes, Chris N ; Scholand, Mary Beth ; Glaspole, Ian ; Kreuter, Michael ; Veale, Andrew ; Decaris, Martin ; Srour, Nadim ; Ryerson, Christopher J. ; Wielders, Pascal ; Kim, Grace Hyun J. ; Bascom, Rebecca ; Hunninghake, Gary ; Cosgrove, Gregory P.

Rationale: Idiopathic pulmonary fibrosis (IPF) is a rare and progressive disease that causes progressive cough, exertional dyspnea, impaired quality of life, and death. Objectives: Bexotegrast (PLN-74809) is an oral, once-daily, investigational drug in development for the treatment of IPF. Methods: This Phase-2a multicenter, clinical trial randomized participants with IPF to receive, orally and once daily, bexotegrast at 40 mg, 80 mg, 160 mg, or 320 mg, or placebo, with or without background IPF therapy (pirfenidone or nintedanib), in an approximately 3:1 ratio in each bexotegrast dose cohort, for at least 12 weeks. The primary endpoint was incidence of treatment-emergent adverse events (TEAEs). Exploratory efficacy endpoints included change from baseline in FVC, quantitative lung fibrosis (QLF) extent (%), and changes from baseline in fibrosis-related biomarkers. Measurements and Main Results: Bexotegrast was well tolerated, with similar rates of TEAEs in the pooled bexotegrast and placebo groups (62/89 [69.7%] and 21/31 [67.7%], respectively). Diarrhea was the most common TEAE; most participants with diarrhea also received nintedanib. Participants who were treated with bexotegrast experienced a reduction in FVC decline over 12 weeks compared with those who received placebo, with or without background therapy. A dose-dependent antifibrotic effect of bexotegrast was observed with QLF imaging, and a decrease in fibrosis-associated biomarkers was observed with bexotegrast versus placebo. Conclusions: Bexotegrast demonstrated a favorable safety and tolerability profile, up to 12 weeks for the doses studied. Exploratory analyses suggest an antifibrotic effect according to FVC, QLF imaging, and circulating levels of fibrosis biomarkers. Clinical trial registered with www.clinicaltrials.gov (NCT04396756).

140

项与 Bexotegrast 相关的新闻（医药）

2025-02-10

·EndPoints

Pliant pauses Phase 2b lung fibrosis study after safety board recommendation, shares plummet

Pliant Therapeutics has slammed the brakes on enrollment and dosing in a mid-stage study of its lung disease candidate in a scenario that some analysts say they have “never seen before.” The West Coast biotech said late Friday that an independent Data Safety Monitoring Board recommended the pause after reviewing data from the Phase 2b BEACON-IPF trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF). But Pliant does not yet know the reason for the DSMB’s recommendation, according to a company release . For now, patients already enrolled will remain in the study, which is still blinded. BEACON-IPF is testing two doses of bexotegrast — which inhibits αvβ6 and αvβ1 integrins — in 270 patients with IPF. It was meant to complete enrollment this quarter with topline data expected next year. The primary endpoint is change from baseline in absolute forced vital capacity at 52 weeks. Pliant’s share price $PLRX slid 58% premarket Monday but it was down by as much as 35% even before the company made the announcement. Leerink analysts said on Sunday that this type of update was a case they had “never seen before.” Although, they noted that the pause is technically voluntary, meaning the study likely didn’t trigger “prespecified stopping criteria for safety or efficacy.” The DSMB may be taking a “conservative stance” by not disclosing the rationale behind its recommendation so long as the trial remains blinded, the analysts added. If that’s the case, Pliant could face a “difficult choice” between unblinding the study to get clarity and staying blinded but trying to work with the DSMB towards a resolution without clarity. “We think the resolution could be something like stopping one of the dose levels, excluding certain patient types, or prohibiting certain background therapies,” the Leerink analysts said. Stifel analysts said Friday the update is “surprising” and “disappointing.” But TD Cowen analysts wrote Sunday they are still “cautiously optimistic” about the bexotegrast program because key opinion leaders they spoke with confirmed that “conduct has been clean.” Other IPF candidates with a similar mechanism have encountered safety issues. Biogen’s anti-αvβ6 monoclonal antibody, dubbed BG00011, was linked with a higher rate of serious adverse events compared with placebo in a Phase 2b trial, including four patient deaths . But bexotegrast’s safety in Phase 1 and Phase 2 studies to date has been “clean,” the Cowen analysts highlighted. In Europe and a handful of other markets, the Phase 2b study is part of a broader, registrational Phase 2b/3 test. Enrollment in the Phase 3 portion was meant to start immediately after the Phase 2b hit its target enrollment. In the US, Pliant expects to have an end of Phase 2 meeting with the FDA before it rolls out advanced development plans.

临床2期

2024-11-21

·GlobeNewswire-Health Care

Pliant Therapeutics to Participate in Upcoming Investor Events

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced participation in the following December investor events. Evercore 7th Annual HealthCONx Conference Members of Pliant’s senior management will meet with investors on Tuesday, December 3, 2024.Citi 2024 Global Healthcare Conference Members of Pliant’s senior management will meet with investors on Wednesday, December 4, 2024.Piper Sandler 36th Annual Healthcare Conference Bernard Coulie, M.D., Ph.D. Pliant’s President and Chief Executive Officer, Keith Cummings, M.D., Pliant’s Chief Financial Officer, and Éric Lefebvre, M.D., Pliant’s Chief Medical Officer, will participate in a fireside chat on Thursday, November 5, 2024, at 8:00 a.m. Eastern Time.Oppenheimer Movers in Rare Disease Summit Keith Cummings, M.D., and Éric Lefebvre, M.D., will participate in the panel discussion “Differentiated Approaches for Pulmonary Diseases” on Thursday, December 12, 2024, as part of an invitation-only event hosted by Oppenheimer. Interested parties may access the live webcast of the Piper Sandler fireside chat by visiting the Investor Relations’ Events & Presentation page of Pliant’s website. The webcast replay will be archived on the Pliant website for 30 days following the conclusion of the event. About Pliant Therapeutics, Inc. Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant has initiated BEACON-IPF, an adaptive Phase 2b/3 trial of bexotegrast in IPF. Pliant is conducting a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α7β1 targeting muscular dystrophies. For additional information, please visit: www.PliantRx.com. Follow us on social media: X, LinkedIn, and Facebook. Investor and Media Contact: Christopher KeenanVice President, Investor Relations and Corporate CommunicationsPliant Therapeutics, Inc.ir@pliantrx.com

临床1期孤儿药快速通道

2024-11-18

·GlobeNewswire-Health Care

Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024

INTEGRIS-PSC featured in an oral late breaker presentation SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the presentation of clinical data at The Liver Meeting® 2024 of the American Association for the Study of Liver Diseases (AASLD) being held in San Diego, California. Bexotegrast, an oral inhibitor of αvβ6 and αvβ1 integrins, was shown to improve markers and symptoms of cholestasis and stabilized markers of liver fibrosis in participants with primary sclerosing cholangitis: Week 24 results from the Phase 2 INTEGRIS-PSC trial In an oral late breaker presentation, Kris Kowdley, M.D., Director, Liver Institute Northwest and Professor of Medicine, Elson S. Floyd College of Medicine at Washington State University, reviewed the positive data from the INTEGRIS-PSC trial that demonstrated bexotegrast was well tolerated across all doses tested and displayed antifibrotic and anti-cholestatic activity across multiple measures in patients with primary sclerosing cholangitis (PSC). Improvements included improvements in liver stiffness, Enhanced Liver Fibrosis (ELF) scores, as well as liver biochemistry and magnetic resonance imaging (MRI). Identification of novel inflammatory serum and urinary protein biomarkers for PSC In a poster presentation, Johanna Schaub, Ph.D., Principal Scientist II, Translational Sciences at Pliant Therapeutics, presented a study that combined two unique proteomic screening approaches to identify novel diagnostic biomarkers in patients with PSC. Results showed the discovery of dozens of putative serum and urine biomarker candidates along with previously described biomarkers, validating this approach. In addition, this approach yielded proteins previously proposed to predict progression in primary biliary cholangitis and cirrhosis, suggesting a role in predicting progression in PSC. The posters presented at AASLD will be made available on the Publications page of the Pliant website, www.PliantRx.com, at the time of presentation. About Pliant Therapeutics, Inc.Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant has initiated BEACON-IPF, an adaptive Phase 2b/3 trial of bexotegrast in IPF. Pliant is conducting a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α7β1 targeting muscular dystrophies. For additional information, please visit: www.PliantRx.com. Follow us on social media X, LinkedIn, and Facebook. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those regarding the safety, tolerability, pharmacodynamics and therapeutic potential of bexotegrast; our plans for the future development of bexotegrast; and bexotegrast’s potential to become a treatment for PSC. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Pliant Therapeutics could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those related to the development and commercialization of our product candidates, including the impact of current regulatory, macroeconomic and marketplace conditions, our reliance on third parties for critical aspects of our development operations, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, including the availability of additional term loans under our loan facility, and our ability to obtain and maintain intellectual property protection for our product candidates. These and additional risks are discussed in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Quarterly Report on Form 10-Q for the period ended September 30, 2024, which is available on the SEC's website at www.sec.gov. Unless otherwise noted, Pliant is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. Investor and Media Contact: Christopher KeenanVice President, Investor Relations and Corporate CommunicationsPliant Therapeutics, Inc.ir@pliantrx.com

孤儿药临床结果临床2期快速通道临床1期

100 项与 Bexotegrast 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
特发性肺纤维化	临床3期	美国	Pliant Therapeutics, Inc.	2023-09-27
特发性肺纤维化	临床3期	日本	Pliant Therapeutics, Inc.	2023-09-27
特发性肺纤维化	临床3期	阿根廷	Pliant Therapeutics, Inc.	2023-09-27
特发性肺纤维化	临床3期	澳大利亚	Pliant Therapeutics, Inc.	2023-09-27
特发性肺纤维化	临床3期	比利时	Pliant Therapeutics, Inc.	2023-09-27
特发性肺纤维化	临床3期	巴西	Pliant Therapeutics, Inc.	2023-09-27
特发性肺纤维化	临床3期	加拿大	Pliant Therapeutics, Inc.	2023-09-27
特发性肺纤维化	临床3期	智利	Pliant Therapeutics, Inc.	2023-09-27
特发性肺纤维化	临床3期	捷克	Pliant Therapeutics, Inc.	2023-09-27
特发性肺纤维化	临床3期	丹麦	Pliant Therapeutics, Inc.	2023-09-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04480840 (INTEGRIS-PSC, GlobeNewswire) 人工标引	临床2期	原发性硬化性胆管炎	36	Bexotegrast	遞膚齋糧構衊築襯窪衊(選範鹹獵繭構襯淵齋鏇) = None 餘糧簾製壓選夢衊窪淵 (簾襯艱餘築餘鹽艱醖積 ) 更多	积极	2024-07-15
				Placebo
NCT04396756 (INTEGRIS-IPF, ATS2024) 人工标引	临床2期	特发性肺纤维化	88	Bexotegrast (40 mg)	淵廠糧壓鏇願鏇蓋餘蓋(夢製築範獵製廠鬱廠網) = 顧鑰鑰艱繭衊鬱鑰鏇憲艱餘積夢鹽膚窪淵鏇選 (觸餘構積觸網壓蓋憲構, 4.80) 更多	积极	2024-05-21
				Bexotegrast (80 mg)	淵廠糧壓鏇願鏇蓋餘蓋(夢製築範獵製廠鬱廠網) = 遞網廠繭網餘願窪鬱糧艱餘積夢鹽膚窪淵鏇選 (觸餘構積觸網壓蓋憲構, 4.19) 更多
ATS2024	N/A	特发性肺纤维化 \| 原发性硬化性胆管炎	-	Bexotegrast	範夢蓋選蓋廠遞壓鏇簾(構構鹹憲遞簾鏇衊選築) = The most common system organ class AEs were gastrointestinal-related, including diarrhea, nausea and constipation 艱簾選構廠衊簾醖淵餘 (遞艱壓襯鬱築鏇鏇顧製 ) 更多	-	2024-05-19
				Placebo
NCT04480840 (INTEGRIS-PSC, Corporate Publications) 人工标引	临床2期	肝纤维化 \| 原发性硬化性胆管炎	121	PLN-74809 40 mg	製構襯窪醖積觸壓鏇糧(醖築遞艱選夢艱壓鑰衊) = 簾範積鑰積餘鬱襯鑰壓願顧選繭構鹹鏇鬱鬱憲 (繭鹽膚選襯構網糧壓築 )	积极	2024-02-04
				PLN-74809 80 mg	製構襯窪醖積觸壓鏇糧(醖築遞艱選夢艱壓鑰衊) = 夢鑰鏇選餘糧積鬱鏇築願顧選繭構鹹鏇鬱鬱憲 (繭鹽膚選襯構網糧壓築 )
NCT04072315 (IPF-201, CTgov)	临床2期	特发性肺纤维化	9	PLN-74809 (60 mg)	觸膚製鹹積繭觸遞膚構(獵顧鬱窪顧夢鹹衊願艱) = 觸製簾淵衊衊遞獵製願鏇遞廠鑰餘夢淵廠糧壓 (簾鬱繭網鏇蓋壓壓鏇遞, 艱顧範遞築簾構選窪齋 ~ 鹽獵築鑰廠獵餘積願襯) 更多	-	2023-12-12
				PLN-74809 (120 mg and 240 mg)	觸膚製鹹積繭觸遞膚構(獵顧鬱窪顧夢鹹衊願艱) = 遞構窪衊醖醖築鹽窪築鏇遞廠鑰餘夢淵廠糧壓 (簾鬱繭網鏇蓋壓壓鏇遞, 顧鏇鬱蓋艱簾鹹夢鹽範 ~ 膚築構簾糧鏇窪網範遞) 更多
NCT04480840 (INTEGRIS-PSC , Corporate Publications) 人工标引	临床2期	肝纤维化 \| 原发性硬化性胆管炎	85	bexotegrast 40 mg	鹹構壓獵觸夢簾膚膚築(窪範衊醖獵齋網構齋糧) = 夢網獵鏇築簾廠選衊襯壓範鏇範淵製範簾鏇襯 (壓簾繭繭衊醖網襯夢製 )	积极	2023-09-26
				bexotegrast80 mg	鹹構壓獵觸夢簾膚膚築(窪範衊醖獵齋網構齋糧) = 範觸獵夢鏇齋顧餘觸遞壓範鏇範淵製範簾鏇襯 (壓簾繭繭衊醖網襯夢製 )
NCT04396756 (INTEGRIS-IPF, ATS2023)	临床2期	特发性肺纤维化	-	PLN-74809 40 mg	鬱夢製鑰夢鬱醖憲窪鑰(構築鑰蓋艱築夢鏇艱淵) = The most common TEAE (incidence of ≥10%) was diarrhea, occurring in 17.9% (12/67; PLN-74809) and 4.3% (1/23; placebo) of participants; all but one event were mild or moderate and all events occurred in participants on approved IPF therapies (nintedanib, n=12; pirfenidone, n=1) 顧觸顧廠築選淵淵襯繭 (淵襯齋衊鏇鬱選獵顧糧 ) 更多	积极	2023-05-21
				PLN-74809 80 mg
ATS2022	N/A	-	-	PLN-74809	淵鬱醖艱鏇襯夢餘築觸(觸餘鏇膚廠膚顧窪餘夢) = 構襯餘襯齋繭蓋範製鬱齋餘窪網膚積顧鹹夢選 (範鑰餘艱糧餘醖艱襯蓋 ) 更多	-	2022-05-15
				Placebo	淵鬱醖艱鏇襯夢餘築觸(觸餘鏇膚廠膚顧窪餘夢) = 遞簾築製壓獵獵廠壓衊齋餘窪網膚積顧鹹夢選 (範鑰餘艱糧餘醖艱襯蓋 ) 更多